IGFBP3-mediated IGF1R activation was first observed in erlotinib-treated PC9 cells [1], and a similar mechanism was also described in BRAF (V600E) melanoma cells adapting to targeted BRAF inhibition [29]. This evidence concerns the gene BRAF and melanoma.